Release date: November 13, 2006
Review date: October 24, 2007
Available for credit through: November 30, 2008
Program Description
Chemotherapy-induced neutropenia has very serious and important clinical consequences in terms of medical care, quality of life, and economic factors for cancer treatment. Chemotherapy patients who develop neutropenia are at risk of developing febrile neutropenia, which is a medical emergency that requires immediate medical management. Febrile neutropenia has historically been treated through the use of prophylactic antibiotics, but their usefulness continues to be controversial and the incidence of febrile neutropenia continues to be high. The use of hematopoetic colony stimulating factors (CSFs) has improved the outcomes for patients who experience febrile neutropenia. Three major oncology organizations have updated their treatment guidelines to reflect new clinical data on the use of CSFs for febrile neutropenia and to highlight updated risk factors for the patients most likely to experience febrile neutropenia. These new guidelines and practical applications of these guidelines will be discussed in this program.
Target Audience
This program is designed specifically for hematologists, medical oncologists, and Pharmacists caring for patients receiving chemotherapy.
Educational Objectives
At the conclusion of this activity, participants will be able to:
Discuss the recommendations of recently-updated guidelines for use of colony stimulating factors (CSFs) from the National Comprehensive Cancer Network (NCCN), the American Society for Clinical Oncology (ASCO), and the European Organization for Research and Treatment of Cancer (EORTC)
Discuss how clinical practices should be changed based on these new guidelines.
Discuss current controversies in preventing neutropenic events
Summarize the latest data about risk factors that predispose cancer patients to adverse outcomes from chemotherapy-induced neutropenia
Apply the use of risk factors, derived from a validated risk assessment model, to clinical cases to determine appropriate patients for CSF support following chemotherapy
There are no fees to participate in this activity. A certificate of completion for physicians and a statement of credit for pharmacists may be printed out after viewing the program and submitting your post-test and evaluation form.
Accreditation
ArcMesa Educators is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
ArcMesa Educators designates this educational activity for a maximum of 1 AMA PRA Category 1 creditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. (o UPN 200-000-06-025-H01-P). Pharmacists will receive 1 contact hour upon completion of this activity.
ArcMesa Educators is an approved provider of continuing education in nursing by the ASNA, an accredited approver by the ANCC Commission on Accreditation. Participants are entitled to receive 1 contact hour upon successful completion of the activity.
Faculty Disclosure Declarations
Jeffrey C. Crawford, MD – Grants/Research Support recipient, Advisory Board, Honorarium recipient – Amgen
David C. Dale, MD – Consultant, Speakers’ Bureau, Grants/Research Support recipient - Amgen
Gary H. Lyman, MD, MPH, FRCP (Edin) – Speakers’ Bureau, Grants/Research Support recipient – Amgen; Speaker’s Bureau – Ortho Biotech
Christopher R. Friese, RN, PhD, AOCN® – Consultant, Speakers’ Bureau/Honorarium recipient, Stock Shareholder – Amgen; Stock Shareholder – Novartis
Shanna J. McClennen, PhD (Medical Writer) – Nothing to disclose
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of Amgen, any other manufacturer of pharmaceuticals, or ArcMesa Educators.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating panelists. Any medications, diagnostic procedures or treatments discussed by the panelists should not be utilized without evaluation of their patient's conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Printer settings may vary. Please use landscape layout option.
Jeffrey C. Crawford, MD Chief, Department of Medicine
Division of Medical Oncology and Transplantation
Duke University Medical Center
David C. Dale, MD Professor of Medicine,
University of Washington
Attending Physician, UWMC - Roosevelt
General Internal Medicine Center
Gary H. Lyman, MD, MPH, FRCP (Edin) Professor of Medicine and Oncology
University of Rochester School of Medicine and Dentistry
Director, Health Services and Outcomes Research
James P. Wilmot Cancer Center
University of Rochester medical Center
Strong Memorial Hospital
Christopher R. Friese, RN, PhD, AOCN® Research Fellow
Center for Outcomes & Policy Research
Dana-Farber Cancer Institute/Harvard School of Public Health
Boston, MA
ArcMesa Educators is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education. (o UPN 200-000-06-025-H01-P). Pharmacists will receive 1 contact hour upon completion of this activity. 
